Rystiggo (rozanolixizumab-noli)

Rystiggo (rozanolixizumab-noli) is a prescription medicine for adult patients with generalized myasthenia gravis (gMG). It is indicated for patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Rystiggo (rozanolixizumab-noli) is approved by the FDA in the USA.

  • Disease Indications : Myasthenia Gravis
  • Manufacturer : UCB
  • Usage : Subcutaneous
Medicine approved by
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • Food and Drug Administration (FDA)